No all-oral, direct-acting antiviral regimens have been approved for children with chronic hepatitis C virus (HCV) infection. We conducted a phase 2, multicenter, open-label study to evaluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents with chronic HCV genotype 1 infection. One hundred patients aged 12-17 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks. On the tenth day following initiation of dosing, 10 patients underwent an intensive pharmacokinetic evaluation of the concentrations of sofosbuvir, ledipasvir, and the sofosbuvir metabolite GS-331007. The primary efficacy endpoint was the percentage of patients with a sustained virologic response at 12 weeks posttreatment. Median age of patients was 15 years (range 12-17). A majority (80%) were HCV treatment-naive, and 84% were infected through perinatal transmission. One patient had cirrhosis, and 42 did not; in 57 patients the degree of fibrosis was unknown. Overall, 98% (98/ 100; 95% confidence interval 93%-100%) of patients reached sustained virologic response at 12 weeks. No patient had virologic failure. The 2 patients who did not achieve sustained virologic response at 12 weeks were lost to follow-up either during or after treatment. The three most commonly reported adverse events were headache (27% of patients), diarrhea (14%), and fatigue (13%). No serious adverse events were reported. Area under the concentration-time curve (tau) and maximum concentration values for sofosbuvir, ledipasvir, and GS-331007 were within the predefined pharmacokinetic equivalence boundaries of 50%-200% when compared with adults from phase 2 and 3 studies of ledipasvir and sofosbuvir. Conclusion: Ledipasvir2sofosbuvir was highly effective at treating adolescents with chronic HCV genotype 1 infection; the dose of ledipasvir2sofosbuvir currently used in adults was well tolerated in adolescents and had an appropriate pharmacokinetic profile. (HEPATOLOGY 2017;66:371-378).
T reatment options available for children with chronic hepatitis C virus (HCV) infection do not reflect the recent advances in care. (1) Although adults with HCV of all genotypes now have the option of receiving a number of highly effective, all-oral treatment regimens, the sole treatment regimen that is currently approved for children is combination therapy with interferon or pegylated interferon and Abbreviations: CI, confidence interval; C max , maximum concentration; HCV, hepatitis C virus; NS5A/B, nonstructural proteins 5A/5B; PK, pharmacokinetic; RAS, resistance-associated substitution; SVR, sustained virological response; SVR12, SVR at 12 weeks posttreatment.
ribavirin for 24 or 48 weeks, depending on the HCV genotype. (2) Chronic HCV infection in children is largely asymptomatic or associated with mild, nonspecific symptoms; however, significant fibrosis or cirrhosis can occur. (3) (4) (5) Some children with chronic HCV may progress to develop hepatocellular carcinoma (6, 7) or end-stage liver disease requiring liver transplantation. (8, 9) In addition, because of side effects, poor tolerability, and the relatively low likelihood of success associated with pegylated interferon and ribavirin treatment, (10) (11) (12) it has been suggested that most children with chronic HCV infection should defer treatment until interferon-free regimens are available. (2) The prevalence of HCV in children varies globally, with estimates of 0.05%-0.36% in the United States and Europe (13) and up to 5.8% in regions of Africa. (14) However, in the United States, HCV infection rates have recently increased among adolescents and young adults, especially in eastern rural regions, in association with the rise of injected opioid use. (15, 16) Given the increase in HCV infection rates among persons entering or within their childbearing years, the risk for perinatal transmission to infants has also risen in many areas. (17) We evaluated the safety and effectiveness of an all-oral, direct-acting antiviral regimen in adolescents 12-17 years old with HCV genotype 1 infection. Participants received 12 weeks of treatment with ledipasvir, a nonstructural protein 5A (NS5A) inhibitor, and sofosbuvir, a potent NS5B polymerase inhibitor. The combination of sofosbuvir and ledipasvir has shown high rates of sustained virologic response (SVR) in adults with HCV genotype 1, including those with compensated cirrhosis. (18) (19) (20) In our study, a subset of patients underwent a period of intensive pharmacokinetic evaluation to determine if children who receive this combination treatment have similar exposure to ledipasvir, sofosbuvir, and GS-331007, a metabolite of sofosbuvir, to that demonstrated in adults.
Patients and Methods

PATIENTS
Eligible patients were 12 to <18 years old and had chronic infection with HCV genotype 1, with plasma HCV RNA levels 10 4 IU/mL. Patients were required to have an absolute neutrophil count 1,500/ mm 3 and a hemoglobin level 11 g/dL. Patients with or without cirrhosis were included; the presence of cirrhosis was determined based on existing biopsy results, but biopsy was not required for study entry. Patients were excluded from participating in the study if they had any of the following: decompensated liver disease; infection with hepatitis A, hepatitis B, or human immunodeficiency virus; alfa-fetoprotein level >50 ng/ mL; serum creatinine >1.5 mg/dL; estimated glomerular filtration rate <90 mL/minute/1.73 m 2 as calculated by the Schwartz formula; daily use of nonsteroidal anti-inflammatory drugs; systemic corticosteroid use for more than 2 weeks (pulmonary/nasal administration was permitted); clinically relevant alcohol or drug abuse within 12 months of screening; or psychiatric hospitalization, suicide attempt, or disability resulting from psychiatric illness within the prior 5 years. Up to 40% of patients could be treatmentexperienced. Parents or legal guardians provided written informed consent before patients undertook any study-related procedures. Patients who could read and write provided written assent.
STUDY DESIGN
In this phase 2, multicenter, open-label study, patients received the ledipasvir-sofosbuvir fixed-dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily, without regard of food, for 12 weeks.
ARTICLE INFORMATION:
On the tenth day following initiation of dosing, 10 patients participated in a pharmacokinetic (PK) leadin cohort and underwent an intensive pharmacokinetic evaluation, following administration of ledipasvir/ sofosbuvir with a standardized meal (400 kcal containing 13 g of fat). To be eligible for the PK lead-in cohort, patients had to weigh 45 kg, be naive to HCV treatment, and have no documented cirrhosis. Patients who completed the PK lead-in were immediately enrolled into the treatment phase with no interruption of study drug administration. After 12 weeks of treatment, follow-up visits were conducted at posttreatment weeks 4, 12, and 24.
The study protocol was approved by the review board or ethics committee of each institution prior to study initiation. The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki.
EFFICACY EVALUATION
Blood samples for determining serum HCV RNA levels were drawn at screening; on day 1 of treatment; at treatment weeks 1, 2, 4, 8, and 12; and at follow-up weeks 4, 12, and 24. Plasma HCV RNA levels were analyzed using the Roche Ampliprep/COBAS TaqMan HCV Test, v2.0 (Roche Molecular Systems, Inc., Branchburg, NJ), which has a lower limit of quantification of 15 IU/mL.
The primary efficacy endpoint was the percentage of patients who achieved SVR at 12 weeks posttreatment (SVR12), defined as HCV RNA less than the lower limit of quantification (15 IU/mL) 12 weeks after stopping the study drugs. The SVR12 rate was calculated with a two-sided 95% exact confidence interval (CI) based on the Clopper-Pearson method. With approximately 100 patients, a two-sided 95.0% CI of the SVR12 rate would extend, at most, 5.9% in both directions from the observed SVR12 rate, assuming the expected SVR12 rate is 90%. Missing SVR values were imputed as a success if bracketed by values that were termed successes.
SAFETY EVALUATIONS
During treatment, vital signs, reported adverse events, concomitant medication intake, and clinical laboratory tests were collected at every visit. Complete physical examinations were conducted on day 1. During every follow-up visit, vital signs and reported adverse events were collected and symptom-directed physical examinations were done. Concomitant medications were reported at the follow-up week 4 visit, and clinical laboratory tests were done at the week 4 and week 12 follow-up visits. Treatment-emergent clinical and laboratory adverse events were summarized using the Medical Dictionary for Regulatory Activities, version 18.1.
At baseline all patients underwent a Tanner pubertal stage assessment. For patients who had received Tanner stage 5 at baseline, no further Tanner staging was done. Those who scored below Tanner 5 underwent Tanner assessments again at the end of treatment and at follow-up weeks 12 and 24.
PK ANALYSES
Serial PK blood samples were collected at the day 10 visit from the first 10 patients enrolled to determine the pharmacokinetics of sofosbuvir, its metabolite GS-331007, and ledipasvir to confirm the appropriateness of the adult ledipasvir2sofosbuvir dose in adolescents before additional patients were enrolled. Single plasma PK samples were collected at all scheduled ontreatment study visits for patients in the treatment phase.
The GS-331007, sofosbuvir, and ledipasvir exposure data from this study were compared to the integrated adult data from phase 2 and 3 clinical studies using an analysis of variance for log-transformed GS-331007, sofosbuvir, and ledipasvir. The 90% CIs were constructed for the ratio of geometric means of the PK parameters area under the concentration-time curve (AUCtau), maximum concentration (C max ), and trough concentration (as appropriate). The equivalence boundary was set as 50%-200%.
RESISTANCE ANALYSES
During treatment and follow-up, plasma samples for viral sequencing were collected at the same time points as for HCV RNA levels. The HCV NS5A and NS5B coding regions were amplified by DDL Diagnostic Laboratory (Rijswijk, Netherlands) using standard RT-PCR technology at baseline for all patients. The PCR products from baseline samples were deepsequenced with an assay cutoff at 1% by DDL. Resistance-associated substitutions (RASs) which were present in >15% of the sequence reads were reported.
Results
PATIENT POPULATION
From November 2014 to October 2015, 100 patients were enrolled at 24 study sites across the United States, United Kingdom, and Australia. The median age of patients was 15 years (Table 1) , and the majority were HCV treatment-naive (80%); 84% were infected through perinatal transmission. Sixty-three percent of patients were female, and 90% were white. Seventy-six percent had a non-CC IL-28B genotype. HCV genotype 1a was present in 81% of patients and 1b in 19%. One patient was known to have cirrhosis, and 42 patients did not have cirrhosis; in the remaining 57 patients the stage of fibrosis/cirrhosis was unknown.
Of the 100 patients who initiated treatment, 99 completed treatment and 1 discontinued treatment and was lost to follow-up (Fig. 1) . Of the 99 who completed treatment, 2 patients did not attend the week 4 and 12 follow-up visits, but 1 of these patients completed a follow-up visit 24 weeks after completing treatment.
VIROLOGIC RESPONSE
Overall, 98% (98/100; 95% CI 93%-100%) of patients reached SVR12 (Table 2 ). Among treatmentnaive patients, 98% (78/80, 95% CI 91%-100%) achieved SVR12. The only person with confirmed cirrhosis, who was treatment-naive, achieved SVR12. Of the 20 treatment-experienced patients in the study, 100% (95% CI 83%-100%) achieved SVR12. *Estimated using Schwartz formula. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; SD, standard deviation.
No patients had virologic nonresponse. Both patients who did not achieve SVR12 were lost to follow-up before completing the posttreatment week 12 visit. The high overall SVR12 rate, with no cases of virologic nonresponse, preclude meaningful interpretation of subgroup analyses.
SAFETY
The three most commonly reported adverse events were headache (27% of patients), diarrhea (14%), and fatigue (13%) ( Table 3) . No patient experienced serious adverse events or discontinued treatment because of an adverse event. All adverse events were mild or moderate in intensity; no patient experienced grade 3 or 4 adverse events. Most laboratory abnormalities were mild in severity; 9 patients (9%) experienced grade 3-4 laboratory abnormalities. Only 1 grade 3 lab abnormality-serum amylase elevation-was experienced by more than 1 patient. The grade 3 serum amylase elevations, which were transient and asymptomatic, were experienced by 3 patients; no pancreatitis was reported. One patient had a grade 4 aspartate aminotransferase elevation (573 U/L) at the week 4 follow-up visit. The aspartate aminotransferase elevation was isolated and associated with the start of isotretinoin treatment for acne. Concurrently, the patient had a grade 2 alanine aminotransferase elevation (155 U/L) but no change in the serum bilirubin level. With continued isotretinoin administration, the patient's aspartate aminotransferase levels subsequently normalized.
Study treatment did not affect development through 12 weeks of follow up after treatment as assessed by Tanner pubertal staging. For males who underwent Tanner staging at posttreatment week 12, 91% (32/35) had no change and 9% (3/35) had an increase in pubic hair staging, and 94% (33/35) had no change and 6% 
PHARMACOKINETICS
The 10 patients enrolled in the PK lead-in cohort had a median age of 16 (range [13] [14] [15] [16] [17] , and most were white (80%) and female (70%). The median weight and body mass index of patients in this group were 68 kg (range 47-87) and 27 kg/m 2 (range 19-35), respectively. Administration of ledipasvir2sofosbuvir 90/400 mg in HCV-infected adolescents provided comparable plasma exposures of sofosbuvir, GS-331007, and ledipasvir to those observed in adults. The AUCtau and C max for sofosbuvir, GS-331007, and ledipasvir in adolescents were within the predefined PK equivalence boundaries of 50%-200% when compared with adults from phase 2 and 3 studies ( Table 4 ). The upper bound of the 90% CI for ledipasvir C max was modestly higher than 200% in adolescents (geometric mean ratio 5 162, 90% CI 125-209); this difference is not considered clinically relevant based on the established exposure-safety analysis for ledipasvir.
RESISTANCE ANALYSES
Deep sequencing for baseline resistance analysis was successful for 97 of all 100 adolescent patients in the trial. With a 15% cutoff, NS5A RASs were detected in 5 of the 100 patients (5%) and included K24G (n 5 1), Q30H (n 5 1), L31M (n 5 1), and Y93H/C (n 5 2) (Table 5) . Similarly, at the 15% cutoff, NS5B polymerase inhibitor RASs were detected in 5 of the 100 patients (5%), including one patient with baseline NS5A RASs at baseline. NS5B polymerase inhibitor RASs detected at baseline included L159F (n 5 1 genotype 1a and n 5 2 genotype 1b), E237G (n 5 1 genotype 1a), and N142T (n 5 1 genotype 1a). All patients with baseline NS5A or NS5B polymerase inhibitor RASs were treatment-naive, and all achieved SVR12.
Discussion
The availability of all-oral, direct-acting antiviral regimens for children with chronic HCV infection is an unmet need. Although the estimated prevalence of HCV infection in children is low (up to 0.4%) in Europe and the United States, (13) there are regions where a substantial number of children are infected. In Egypt, for example, the HCV seroprevalence rate is 6% in children, largely related to unsafe injection practices during a campaign of parenteral antischistosomiasis treatment in the 1960s-1980s. (21) Approximately 4%-6% of children with chronic HCV infection have evidence of advanced fibrosis or cirrhosis, and some children eventually require liver transplantation for end-stage liver disease as a consequence of HCV infection. (22) Despite well-established guidelines for treating HCV in adults, there is no universal consensus on when or if to treat chronic HCV infection in children. Treatment of pediatric patients has been controversial as the current standard of care, pegylated interferon and weight-based ribavirin, is associated with significant side effects, including growth impairment, and poor tolerability. (10) (11) (12) In adults, all-oral, direct-acting HCV regimens offer the benefits of greater tolerability, improved response rates, fewer adverse events, easier administration, and shorter duration relative to pegylated interferon and ribavirin. (23) Multiple direct-acting HCV regimens are available for adults with HCV genotype 1 infection. In the meantime, many children with chronic HCV have deferred treatment until these newer options receive approval for pediatric use, (24) putting them at risk for disease progression.
In our study, treatment with the direct-acting antivirals ledipasvir and sofosbuvir for 12 weeks was highly effective at treating adolescents with chronic HCV genotype 1 infection, with an overall SVR rate of 98%. The 2 patients who did not achieve SVR12 were lost to followup. The presence of RASs at baseline did not affect treatment response; all 9 patients with a baseline NS5A or NS5B RAS achieved SVR12. Overall, there was no apparent difference in the prevalence of baseline NS5A RASs in adolescents compared with adults, although the number of adolescent patients was relatively small.
In general, the adverse events noted in this study were consistent with those reported in prior studies of ledipasvir2sofosbuvir in adults. Similar to what has been observed in adults, treatment with ledipasvir2 sofosbuvir was well tolerated in adolescents. (18, 19) The most commonly reported events in this study, headache, diarrhea, and fatigue, have been reported in adult populations. (18, 19) Notably, based on Tanner pubertal staging, 12 weeks of ledipasvir2sofosbuvir did not affect short-term development.
Although our study included only HCV genotype 1 patients, given the similarity of chronic HCV infection in children and adults, the efficacy data in this study and the comparable exposure suggest the possibility for extrapolation to other genotypes. However, it is unknown whether pediatric patients treated outside the context of a clinical trial would have similarly high success rates with ledipasvir2sofosbuvir. In this study, only 1 patient had cirrhosis, and therefore the combination of ledipasvir2sofosbuvir in adolescents with cirrhosis warrants further study.
Successful treatment of children with HCV could have several public health benefits, including reductions in the rates of disease progression and transmission. Data from adults indicate that successful treatment with ledipasvir2sofosbuvir leads to improvements in quality of life. (25) In summary, ledipasvir2sofosbuvir was highly effective at treating adolescents with chronic HCV genotype 1 infection. The dosing of ledipasvir2sofosbuvir currently used in adults was well tolerated and had comparable PK exposure. The availability of an alloral, direct-acting antiviral regimen for adolescents with chronic HCV infection would improve care for patients who currently have limited treatment options.
